CO2021016623A2 - Uso de co-cristales de tramadol y celecoxib para el tratamiento del dolor mientras se reduce la responsabilidad por abuso de tramadol - Google Patents

Uso de co-cristales de tramadol y celecoxib para el tratamiento del dolor mientras se reduce la responsabilidad por abuso de tramadol

Info

Publication number
CO2021016623A2
CO2021016623A2 CONC2021/0016623A CO2021016623A CO2021016623A2 CO 2021016623 A2 CO2021016623 A2 CO 2021016623A2 CO 2021016623 A CO2021016623 A CO 2021016623A CO 2021016623 A2 CO2021016623 A2 CO 2021016623A2
Authority
CO
Colombia
Prior art keywords
tramadol
pain
treatment
addiction
celecoxib
Prior art date
Application number
CONC2021/0016623A
Other languages
English (en)
Inventor
Gregorio-José Encina-García
Carlos-Ramón Plata-Salamán
Original Assignee
Esteve Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Pharmaceuticals Sa filed Critical Esteve Pharmaceuticals Sa
Publication of CO2021016623A2 publication Critical patent/CO2021016623A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere al uso de co-cristales de tramadol y celecoxib para el tratamiento del dolor, para prevenir el riesgo de adicción al tramadol, para el tratamiento del dolor y al mismo tiempo reducir la propensión al abuso del tramadol, para el tratamiento del dolor también reduciendo una incidencia de adicción al tramadol, para el tratamiento del dolor previniendo una adicción al tramadol, para el tratamiento del dolor en un paciente con adicción al tramadol o el riesgo de sufrirlo, para el tratamiento del dolor e inhibir, retrasar, reducir o revertir adicción al tramadol o para el tratamiento del dolor y reducción de la incidencia de adicción al tramadol.
CONC2021/0016623A 2019-05-14 2021-12-07 Uso de co-cristales de tramadol y celecoxib para el tratamiento del dolor mientras se reduce la responsabilidad por abuso de tramadol CO2021016623A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19382377 2019-05-14
PCT/EP2020/063250 WO2020229502A1 (en) 2019-05-14 2020-05-13 Use of co-crystals of tramadol and celecoxib for treating pain while reducing the abuse liability of tramadol

Publications (1)

Publication Number Publication Date
CO2021016623A2 true CO2021016623A2 (es) 2022-01-17

Family

ID=66589491

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0016623A CO2021016623A2 (es) 2019-05-14 2021-12-07 Uso de co-cristales de tramadol y celecoxib para el tratamiento del dolor mientras se reduce la responsabilidad por abuso de tramadol

Country Status (14)

Country Link
US (2) US20230020469A1 (es)
EP (1) EP3968978A1 (es)
JP (1) JP2022533580A (es)
KR (1) KR20220008301A (es)
CN (1) CN113825501A (es)
AU (1) AU2020276711A1 (es)
BR (1) BR112021020893A2 (es)
CA (1) CA3137381A1 (es)
CO (1) CO2021016623A2 (es)
IL (1) IL287955A (es)
MA (1) MA55954A (es)
MX (1) MX2021013123A (es)
SG (1) SG11202111390TA (es)
WO (1) WO2020229502A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2177215A1 (en) * 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and NSAIDs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2177215A1 (en) * 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and NSAIDs
EP2586432A3 (en) * 2009-10-16 2013-07-10 Laboratorios Del Dr. Esteve, S.A. Co-crystals of Tramadol and NSAIDs like Coxibs
EP2311446A1 (en) * 2009-10-16 2011-04-20 Laboratorios Del. Dr. Esteve, S.A. Compositions comprising Tramadol and Celecoxib in the treatment of pain
CN102573825B (zh) * 2009-10-16 2015-04-22 埃斯蒂文博士实验室股份有限公司 曲马多与昔布类的共晶体
EP2392319A1 (en) 2010-06-04 2011-12-07 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical compositions of co-crystals of tramadol and coxibs
JP6323846B2 (ja) * 2016-04-07 2018-05-16 塩野義製薬株式会社 オピオイドを含有する乱用防止製剤
WO2018119033A1 (en) * 2016-12-20 2018-06-28 Cima Labs Inc. Abuse-resistant and abuse-deterrent dosage forms

Also Published As

Publication number Publication date
IL287955A (en) 2022-01-01
MX2021013123A (es) 2021-11-18
KR20220008301A (ko) 2022-01-20
CN113825501A (zh) 2021-12-21
JP2022533580A (ja) 2022-07-25
MA55954A (fr) 2022-03-23
CA3137381A1 (en) 2020-11-19
AU2020276711A1 (en) 2021-11-18
BR112021020893A2 (pt) 2022-04-19
US20230020469A1 (en) 2023-01-19
US20200360306A1 (en) 2020-11-19
WO2020229502A1 (en) 2020-11-19
SG11202111390TA (en) 2021-11-29
EP3968978A1 (en) 2022-03-23

Similar Documents

Publication Publication Date Title
MX2020011562A (es) Agonistas del receptor de la hormona tiroidea y usos de los mismos.
MX2023007754A (es) Una composicion que comprende un anticuerpo inhibidor de masp-2 para su uso en el tratamiento de la nefropatia por inmunoglobulina a (igan) dependiente de esteroides.
CL2018000377A1 (es) Mecanismo de resistencia a inhibidores de bromodominio bet
PH12019501216A1 (en) New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
WO2018234568A3 (en) HYDROXYNORKETAMINE FOR USE IN TREATING DEPRESSION
PH12020500276A1 (en) Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant
NZ739392A (en) Methods for treating hepcidin-mediated disorders
PH12021550558A1 (en) Modulators of pnpla3 expression
MX2019009908A (es) Combinacion de un agonista de ppar con un agonista de fxr.
EP4279127A3 (en) Growth differentiation factor 15 as biomarker for metformin
PL3866772T3 (pl) 2,3,5-trimetylo-6-nonylocykloheksa-2,5-dieno-1,4-dion do hamowania i leczenia alfa-synukleinopatii, tauopatii i innych zaburzeń
CL2017002214A1 (es) Formulación de combinación de tesofensina y betabloqueante
CL2020002544A1 (es) Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret
NZ758177A (en) Modulators of pcsk9 expression
CO2021016623A2 (es) Uso de co-cristales de tramadol y celecoxib para el tratamiento del dolor mientras se reduce la responsabilidad por abuso de tramadol
WO2015112902A3 (en) CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN
WO2019157495A3 (en) Methods for preventing and/or treating bone loss conditions by modulating irisin
PH12020551573A1 (en) Pharmaceutical compositions for inhibiting inflammatory cytokines
JOP20200291A1 (ar) معدلات التعبير عن apol1
MX2020009942A (es) Compuestos y usos de los mismos.
CO2019005247A2 (es) Composición farmacéutica para evitar la adicción a opioides
PH12021551138A1 (en) Application of chidamide in combination with r-chop, and drug combination
MX2022006750A (es) Inhibidores de masp-2 y metodos de uso.
MX2021005766A (es) Métodos de gestión de eventos adversos en pacientes con inflamación.